Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Title Source Codes Date
Top 10 at 10: $13m lithium farm-ins and a massive 100pc takeover premium

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead PAR 2 weeks ago
ASX stocks striving to inject youthfulness into an aging world population

Every country worldwide is seeing growth in both size and percentage of older people in their population Lodge Partners says anti-aging and longevity has become a focus area for pharmaceutical and biotech companies LTR Pharma is helping ol...

Stockhead PAR 1 month ago
ASX Health Stocks: Paradigm takes another step forward as Phase 2 trial meets primary endpoint

Paradigm Biopharma’s Phase 2 meets primary endpoint TrivarX collaborates with US university to advance sleep research   Paradigm’s successful Phase 2 trial Paradigm Biopharma (ASX:PAR) announced that its Phase 2 clinical trial, PARA_MPSVI...

Stockhead PAR 1 month ago
Research To Download: Actinogen, Freelancer, Lepidico, State Gas, & More

Research reports on ASX-listed companies, to download in full. **** -Actinogen Medical ((ACW)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=2B537F21-A3D7-CB04-98294578CBAE8E12 -Amaero International ...

FNArena PAR 4 months ago
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Tim Boreham highlights the success of Paradigm Biopharmaceuticals' joint pain drug ahead of a capital raising. by Tim Boreham ASX code: ((PAR)) Share price: 41.5c Shares on issue: 281,756,625 (pre capital raise) Market cap: $116.9 m Executi...

FNArena PAR 4 months ago
CRITERION: Paradigm’s set for a proper knees-up if its arthritis fighter is the real deal

Despite improving sentiment in the life sciences sector, investors are savagely discounting pre-clinical drug developers with a long path to approval. That’s fair enough – investors are risk averse generally – but many worthy drug developer...

Stockhead PAR 4 months ago
TMH Market Close: ASX200 starts November strong, real estate and health care lead gains

The ASX200 started November with a gain of more than three-quarters of a per cent (.85 of a per cent). Most sectors were in the green. Real estate and health care both had strong runs. In the green BHP Group (ASX:BHP) was up 1.5 pe...

themarketherald.com.au PAR 4 months ago
Why Core Lithium, New Hope, Paradigm, and Sayona Mining shares are sinking today

The S&P/ASX 200 Index (ASX: XJO) is having a strong session on Wednesday. In afternoon trade, the benchmark index is up 0.65% to 6,825.3 points. Four ASX shares that have failed to follow the market's lead today are listed below. Here...

Motley Fool PAR 4 months ago
ASX Health Stocks: IDT on strong growth trajectory, Paradigm smashed 30pc on cap raise

IDT provides strong quarterly update Paradigm tumbles 30pc after emerging from trading halt   IDT’s growth driven by all business segments Victoria-based pharmaceutical manufacturing company, IDT Australia (ASX:IDT), provided an update on...

Stockhead PAR 4 months ago
10 at 11ish: Magnum Mining inks Saudi deal, Novonix scores US$100m grant

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Stockhead PAR 4 months ago
Guess which ASX All Ords share is crashing 34% to a 52-week low

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has returned from its trading halt and crashed deep into the red. In morning trade, the ASX All Ords share is down 34% to a 52-week low of 40.5 cents. Why is this ASX All Ords shar...

Motley Fool PAR 4 months ago
Closing Bell: Orbiting the ASX at 220pc, TG Metals successfully separates ahead of ASX hard landing

Benchmark ASX closes below 6,800 points  All Sectors in red, but for IT Small caps led, in a very big way, by TG6    The benchmark has ended sharply lower after weak overseas leads, strong retail data and an all-round international-flavou...

Stockhead PAR 4 months ago
In Case You Missed It: Lithium hits and a West African gold producer in the takeover crosshairs

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead PAR 4 months ago
Research To Download: Amaero, Bell Financial, Pointerra, Wrkr, and others

Research reports on ASX-listed companies, to download in full. **** -Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=BF0A410A-F5BF-4E00-5CA139523262B26D –Bell Financial Gro...

FNArena PAR 5 months ago
ASX closes 0.3% higher as China’s GDP grows

The Australian sharemarket increased in value on Wednesday, as China's gross domestic product (GDP) for July-September grew by 4.9% compared to the previous year.  At the closing bell, the S&P/ASX 200 was 0.3 per cent higher at 7,077.60...

ShareCafe PAR 5 months ago
3 ASX healthcare shares up 10% to 22% on news

There have been some big movers in the healthcare sector on Wednesday. Here's why these ASX healthcare shares are up over 10% today: Mayne Pharma Group Ltd (ASX: MYX) The Mayne Pharma share price is up over 13% to $3.12. Investors have be...

Motley Fool PAR 5 months ago
Stocks of the Hour: Whitehaven Coal, Paradigm Biopharma, Noxopharm, Liontown Resources

  Don't miss Friday's webinar discussing imaging tech, laser tech and agricultural REITs. Click here to register. Whitehaven Coal (ASX:WHC) has been placed in a trading halt following an announcement by BHP that Whitehaven Coal is the prefe...

ShareCafe PAR 5 months ago
Stocks of the Hour: Whitehaven Coal, Paradigm Biopharma, Noxopharm, Liontown Resources

18 Oct 2023 - A snapshot of the stocks on the move, featuring Whitehaven Coal (ASX:WHC), Paradigm Biopharmaceuticals (ASX:PAR), Noxopharm (ASX:NOX) and Liontown Resources (ASX:LTR)…

FNN PAR 5 months ago
Paradigm Biopharma tests show reverse knee degradation in osteoarthritis patients

Paradigm Biopharma (ASX:PAR) reports it has proven it can reverse the degradation of cartilage in patients with osteoarthritis The company is using injectable pentosan polysulfate sodium (iPPS) delivered twice weekly over six weeks...

themarketherald.com.au PAR 5 months ago
ASX Today: Stocks to watch on Monday

ASX futures were down 0.43 per cent at 8.30 am AEDT as US indexes landed in the red on Friday. The S&P 500 ended down by half a per cent and the NASDAQ down 1.23 per cent. The Dow Jones ended up 0.12 per cent. In the US, energy w...

themarketherald.com.au PAR 5 months ago
Paradigm Biopharmaceuticals (ASX:PAR) – Webinar Presentation

  Paul Rennie – Founder and Managing Director – Paradigm Biopharmaceuticals Limited (ASX:PAR) is a global biopharmaceutical company. Its current focus is a drug for the treatment of osteoarthritis.

ShareCafe PAR 5 months ago
ASX closes 1% higher following rhetoric from US Fed

The S&P/ASX 200 surged back above 7000 on Tuesday, driven by a shift in rhetoric from US Federal Reserve members towards a more dovish stance and signs of easing inflation. The benchmark closed 1% higher at 7040, marking its best one-da...

ShareCafe PAR 5 months ago
In Case You Missed It: Bumper quarter for aged care tech and a global agricultural deal

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead PAR 5 months ago
‘Remarkable outcome’: Paradigm achieves outstanding results in phase II osteoarthritis trial

  Paradigm Pharmaceuticals phase II study for treatment of knee osteoarthritis reports successful outcome at day 356 Clinical outcomes improvement observed for iPPS twice weekly compared to placebo control Company now intends to proceed wi...

Stockhead PAR 5 months ago
ASX Health Stocks: Paradigm to seek TGA nod after successful trial; EMVision uses AI simulation

Paradigm Biopharma set to submit application to TGA EMVision uses artificial intelligence simulation   Paradigm to submit TGA application after successful trial Paradigm Biopharmaceuticals (ASX:PAR) jumped 13% this morning after reporting...

Stockhead PAR 5 months ago
Paradigm clocks 1-year trial result showing iPPS osteo pain decrease

Paradigm Biopharma (ASX:PAR) reports injectable pentosan polysulfate has led to a decrease in self-reported pain in osteoarthritis (OA) patients The company says results show iPPS is likely a superior drug compared to other major treatm...

themarketherald.com.au PAR 5 months ago
Guess which ASX healthcare share is rocketing 18% today

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been catching the eye on Tuesday. At one stage today, the ASX healthcare share was up over 18% to 73.5 cents. The Paradigm share price has pulled back a touch since then but re...

Motley Fool PAR 5 months ago
ASX up 1.1% at noon as oil prices hold steady

Oil prices held steady following a significant surge as Israel indicated that its retaliation against Hamas attacks had just begun, raising concerns of increased instability in the region. The conflict's potential impact on global oil suppl...

ShareCafe PAR 5 months ago
Paradigm’s iPPS shown to reduce cartilage loss and improve function in osteoarthritis patients

Late-stage drug development company Paradigm Biopharmaceuticals (ASX: PAR) has announced positive study data from a Phase 2 clinical trial of injectable pentosan polysulfate sodium (iPPS) for the treatment of acute pain associated with knee...

smallcaps.wpenginepowered.com PAR 5 months ago
Stocks of the Hour: Atlantic Lithium, Raiden Resources, Paradigm Biopharmaceuticals

10 Oct 2023 - A snapshot of the stocks on the move, featuring Atlantic Lithium (ASX:A11), Raiden Resources (ASX:RDN) and Paradigm Biopharmaceuticals (ASX:PAR).

FNN PAR 5 months ago
Stocks of the Hour: Atlantic Lithium, Raiden Resources, Paradigm Biopharmaceuticals

  Atlantic Lithium (AIM:ALL, ASX:A11, OTCQX:ALLIF) receives authorisation to commence the diversion of the transmission lines crossing the Mankessim Licence, moving a step closer to shovel readiness at the Ewoyaa Lithium Project. Shares are...

ShareCafe PAR 5 months ago
Top 10 at 11: Juicy berries and autonomous cop drones got the market jingling this morning

Stockhead’s Top 10 at shortly-before-11-ish, produced with gritted teeth as, once again, the local council has decided that it needs to pay some drongo to stand outside my house all day waving a leaf blower around while screaming into his c...

Stockhead PAR 5 months ago
Research To Download: Pharma & Biotech, Pointerra, Rent.com.au, & More

Research reports on ASX-listed companies, to download in full. **** –Amaero International ((3DA)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=740BB0E6-015D-39AE-7477F8A8DFBEC04C –Millennium Service...

FNArena PAR 7 months ago
Research To Download: Cannindah, Comms, Hot Chili, Kinatico & Lithium Power

Research reports on ASX-listed companies, to download in full. **** –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=628D02C0-B9D8-EA23-2DB35CB4E58A7CBE –AFT Pharmaceuticals ((AFT)) by Edi...

FNArena PAR 8 months ago
Why Latin Resources, Paradigm, Sunland, and Weebit Nano shares are falling

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. The benchmark index is currently down 0.15% to 7,235.2 points. Four ASX shares that are falling more than most today are listed below. Hereâ€...

Motley Fool PAR 8 months ago
ASX Today: Stocks to watch on Tuesday

Futures suggest Australian shares will open relatively unchanged in the face of the RBA interest rate decision this afternoon. Here are some ASX-listed companies with news out today: In healthcare, Paradigm Biopharmaceuticals (PAR) h...

themarketherald.com.au PAR 8 months ago
Research To Download: Kinatico, Qantm, State Gas & Vection Technologies

Research reports on ASX-listed companies, to download in full. **** –AFT Pharmaceuticals ((AFP)) – Edison Research: https://www.fnarena.com/index.php/download-article/?n=5CCC26AF-A670-63C8-370E356F819BE3C4 –Barrow Handley Global Share Fund...

FNArena PAR 9 months ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead PAR 9 months ago
ASX Health Stocks: Paradigm Bio says drug effective in dogs, HeraMED signs deal in US

Paradigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-based global SaaS platform The first patient has been dosed in Imugene’s clinical trial   Late stage biotech Paradigm Biopharmaceuticals (ASX...

Stockhead PAR 9 months ago
Market Highlights: ASX to fall; debt ceiling vote passed but traders fear it may cause a recession

The ASX is set to open lower on Thursday US debt ceiling deal passed to Senate after the House voted 241-187 Crude prices have fallen by another -2.7%   Aussie shares are set to open lower on Thursday after the shock inflation report yest...

Stockhead PAR 9 months ago
Hope for knee osteoarthritis sufferers with advent of global clinical trial.

Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy. MELBOURNE, Australia, May 25, 2023 /PRNewswire/ — With the launch of a new website dedicated to their global clinical trials...

FNArena PAR 10 months ago
Research To Download: Actinogen, Amaero, Pointerra, Respiri, Ricegrowers, Schrole, And More

Research reports on ASX-listed companies, to download in full. –Actinogen Medical ((ACW)) by Edison Research: https://www.fnarena.com/index.php/download-article/?n=F863639F-EF2C-E5CB-37099553DD439B58 –AFT Pharmaceuticals ((AFP)) by Edison R...

FNArena PAR 10 months ago
TMH Market Close: ASX 200 scrapes into the green

The ASX closed in the green, despite teetering around midday after RBA Governor Philip Lowe dampened confidence that interest rates may peak. Mr Lowe warned Australians that the pause may be just temporary, and further interest rate hike...

themarketherald.com.au PAR 11 months ago
Paradigm Biopharmaceuticals’ (ASX:PAR) iPPS demonstrates multiple DMOAD signals in phase two study

Paradigm Biopharmaceuticals (PAR) claims a trial of its injectable pentosan polysulfate sodium (iPPS) drug shows the treatment may slow disease progression in knee osteoarthritis (OA) The company has reported data from day 168 of its pha...

themarketherald.com.au PAR 11 months ago
Why Energy Resources, Paradigm, Piedmont Lithum, and Seek shares are dropping today

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and slipped into the red. At the time of writing, the benchmark index is down slightly to 7,221.3 points. Four ASX shares that are falling more tha...

Motley Fool PAR 11 months ago
ASX Health Stocks: Paradigm shows good Phase 2 results, Race Oncology jumps 8pc after third party report on Zantrene

Paradigm Biopharma demonstrates efficacy of knee osteoarthritis drug Race Oncology released a third-party report showing the potential for Zantrene Emyria and Aspen Australia have signed an exclusive binding deal   Paradigm Biopharmaceuti...

Stockhead PAR 11 months ago
CLOSING BELL: ASX closes higher to end week, materials leading bourse upwards

ASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of possible start of US recession next week spanning 3 quarters, but talk of pause in Aussie rate hikes ‘premature’ Hubify subsidiary Broadland So...

Stockhead PAR 11 months ago
Why Appen, Core Lithium, Paradigm, and Sayona Mining shares are racing higher

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week (and year) in a positive fashion. In afternoon trade, the benchmark index is up 0.55% to 7,057.8 points. Four ASX shares that are climbing more than most today are listed b...

Motley Fool PAR 1 year ago
Paradigm Biopharmaceuticals (ASX:PAR) receives notice of allowance for US patent

Paradigm Biopharmaceuticals (PAR) receives a notice of allowance from the US Patent and Trademark Office (USPTO) The notification demonstrates PAR’s patent application has been examined and satisfies the requirements for patentability The p...

themarketherald.com.au PAR 1 year ago
Market Highlights: ASX to rise, oil price volatility, and 5 small caps to watch on Wednesday

The ASX is poised to open higher on Wednesday after a rally in New York Oil prices higher as Saudi said OPEC+ wasn’t considering output increase Crypto broker Genesis near bankcruptcy The ASX is set to open higher on Wednesday after a bro...

Stockhead PAR 1 year ago